SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001636050-20-000055
Filing Date
2020-10-09
Accepted
2020-10-09 07:00:46
Documents
16
Period of Report
2020-10-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axon-20201009.htm   iXBRL 8-K 52433
2 EX-99.1 exhibit991100920.htm EX-99.1 13819
8 GRAPHIC image011.jpg GRAPHIC 5086
  Complete submission text file 0001636050-20-000055.txt   233171

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axon-20201009.xsd EX-101.SCH 2421
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT axon-20201009_cal.xml EX-101.CAL 712
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT axon-20201009_def.xml EX-101.DEF 1649
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axon-20201009_lab.xml EX-101.LAB 27110
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axon-20201009_pre.xml EX-101.PRE 14217
9 EXTRACTED XBRL INSTANCE DOCUMENT axon-20201009_htm.xml XML 12647
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 201232072
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences